Eisai has expanded its operations into South Africa, with the filing of two products, Halaven (eribulin mesylate) for metastatic breast cancer (BC) and Fycompa (perampanel) for epilepsy, to the Medicines Control Council. Eisai's continued growth is part of the company's Hayabusa plan to have a presence in the top 20 pharmaceutical markets and deliver effective treatments to more than 500 million patients by 2015.
The filing for Halaven is based on data obtained from the EMBRACE study, which provided evidence of a significant overall survival benefit compared with other single-agent chemotherapies. Discovered and manufactured by Eisai, Fycompa has been approved by the EC and is now available in the UK, Germany, Austria, Denmark, Sweden and Norway as an adjunctive therapy for patients with partial onset seizures aged 12 years and above.
To respond to changing needs in the emerging markets, in its Fiscal Year 2011 Annual Report, Eisai set out its aims to transform its businesses in the Era of Great Globalization, in accordance with the Med-term Strategic Plan "Hayabusa". The company is expanding its businesses through contributions to healthcare in East Asia (including Japan and China) and the emerging markets as a driver for growth. In 2011, Eisai established a New Markets and ASEAN Region Division (NM-ASEAN) to initiate business in Central and South America, Russia, Turkey, Canada, Oceania and Africa, and to further expand the business in India, the Middle East and ASEAN countries.
In 2011, the value of the South African pharmaceutical market at retail prices was approximately US$4,335 million. In 2012, taking into consideration current economic performance and the pharmaceutical market, Espicom projected a CAGR of 8.0 per cent in local terms and 1.2 per cent in US dollar terms between 2011 and 2016 that would bring South Africa's pharmaceutical market to US$4.6 billion in 2016, ranking as the fifth largest market in the MEA region, behind Turkey, Egypt, Israel and Saudi Arabia.